Inquiry Contact

Home
Who we are
Why Choose Us
Botanical Extracts

Phytochemicals

Cosmoceuticals

Oleoresins
Other Health Ingredients
Therapeutic Applications
Premixes & Formulas
Consulting & Contract Research
Exhibitions
Testimonials

 

 

LANCONONE PREMIXES FORMULAS
  Supports healthy joints.  
RESEARCH STATUS
Clinical data Pending
Preclinical data Available
Short term Toxicity data Available
Long term Toxicity date Pending
Phytochemical standardization Pending












Inflammatory conditions occur in several common disorders including rheumatoid arthritis, osteoarthritis, lumbago, etc… Selective COX2 inhibitory activity has come under a cloud due the recent controversy regarding Bextra, Celebrex and Vioxx. Natural agents containing more than one anti-inflammatory compounds are expected to act by multiple mechanisms. The commonest adverse effects of COX inhibitors (particularly COX1 inhibitors like Aspirin) are gastric irritation effects and if overused, gastric ulcerations. Due to multiple mechanisms of the multiple phyto-compounds, lower doses may be acting synergistically in herbs. Hence the value of newer anti-inflammatory herbs that have been proven safe and active.

Lanconone is balanced combination of extracts which has scientifically demonstrated significant Antiinflammatory activity.

Dosage / Suggested Use: As a dietary supplement take 1 capsules 3 times a day.

PHARMACOLOGICAL EFFECTS OF ENTOX

Model Dose Results
Antiinflammatory activity by Carageenan induced hind paw oedema in rats. Lanconone 400 mg/kg body wt
Standard drug Diclofenac 10mg/kg
Lanconone reduced the inflammation to the extent of 72.83% and 75% at 4th and 6th hour, respectively which is significantly comparable to the standard drug.


CLINICAL STUDY OUTLINE

Design: A Double Blind, Randomized, Parallel group, Multicentric study.

Objective: To investigate the safety, tolerability and efficacy of LANCONONE- " A Dietary
Supplement" in providing relief from symptoms of pain, stiffness and immobility to patients with moderate conditions of Osteoarthritis of the knee.

Duration of Treatment: 12 weeks

Number of subjects: 30

SAFETY
Acute Oral Toxicity study
The LD50 established at > 2 gm/kg

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, treat or prevent any disease.
 
<< BACK     

Copyright 2004, All Rights Reserved